Adma Biologics Inc. (ADMA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Adma Biologics Inc. (ADMA:NASDAQ), powered by AI.

Current Price
$8.71
P/E Ratio
14.1
Market Cap
2.1B
Sector
Healthcare
What is the Adma Biologics Inc. stock price forecast?

Adma Biologics Inc. is currently trading at $8.71. View real-time AI analysis on Alpha Lenz.

What is Adma Biologics Inc. insider trading activity?

View the latest insider trading data for Adma Biologics Inc. on Alpha Lenz.

What is Adma Biologics Inc.'s P/E ratio?

Adma Biologics Inc.'s P/E ratio is 14.1.

Adma Biologics Inc.

NASDAQ · ADMA
$8.71-0.08(-0.97%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Adma Biologics Inc.'s future dividend policy...
Alpha Chat Insight

Adma Biologics Inc. trades at a P/E of 14.1 (undervalued) with strong ROE of 35.6%. 3Y revenue CAGR of 49.0% highlights clear growth momentum.

Ask for details

Company Overview

Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious diseases. At the core of its operations is the processing of human plasma to produce immunoglobulin products aimed at addressing immune deficiencies and other complex health conditions. The company's prominent products include Bivigam, an intravenous immunoglobulin used for the treatment of primary humoral immunodeficiency, and Asceniv, another intravenous immunoglobulin specifically tailored with hyperimmune antibodies. Adma Biologics serves critical roles within the healthcare sector, particularly in treating patients with immune system disorders, thus supporting a niche yet vital component of the pharmaceutical supply chain. Their products are crucial in meeting the demands of patients who require regular immune system support, distilling unique proteins and antibodies from donated plasma to help bolster patient health. With headquarters in Ramsey, New Jersey, and Boca Raton, Florida, the company plays a significant role in the advancements of plasma-derived therapeutics, catering to both domestic and international needs.

CEOMr. Adam S. Grossman
SectorHealthcare
IndustryBiotechnology
Employees685

Company Statistics

FY 2025

Profile

$2.07BMarket Cap
$510.17MRevenue
0.00Shares Out
685Employees

Margins

57.39%Gross
39.44%EBITDA
37.53%Operating
35.80%Pre-Tax
28.80%Net

Valuation

14.12P/E
4.35P/B
4.07EV/Sales
10.27EV/EBITDA
75.42P/FCF

Growth (CAGR)

49.05%Rev 3Yr
64.60%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

26.40%ROA
35.56%ROE
34.10%ROIC

Financial Health

$87.63MCash & Cash Equivalents
$59.29MNet Debt
30.78%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Adma Biologics Inc. (ticker: ADMA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 685 employees. Market cap is $2.1B.

The current price is $8.705 with a P/E ratio of 14.12x and P/B of 4.35x.

ROE is 35.56% and operating margin is 37.53%. Annual revenue is $510M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Adma Biologics Inc. (ADMA) Stock Forecast 2026 $8.71 — Price, Financials & Analyst Targets | Alpha Lenz